Below is information about articles being published in the September 17 issue of Annals of Internal Medicine. The information is not intended to substitute for the full article as a source of information. Annals of Internal Medicine attribution is required for all coverage.
Extending meningococcal vaccine recommendations could significantly reduce risk for infection
It has been suggested that patients infected with HIV are at increased risk for invasive meningococcal disease (IMD), but the connection has not been fully described. Both IMD and HIV are reportable illnesses. In New York City (NYC), cases are reported to the Department of Health and Mental Hygiene (DOHMH). To determine the risk for IMD and death in people living with HIV/AIDS in NYC, DOHMH researchers compared records of IMD cases from 2000-2011 to the Cityís death and HIV registries. The researchers found that patients living with HIV/AIDS were at increased risk for contracting IMD. The majority (87%) of IMD infections among patients living with HIV/AIDS were potentially vaccine-preventable. In 2005, a new IMD vaccine was approved and recommended for routine use in young adolescents with HIV. Extending these recommendations to include vaccinating adults with HIV could significantly reduce risk for infection. Cost effectiveness and vaccine efficacy studies are needed.